1613712-46-1

Basic information

• Product Name: C₂₁H₁₆BrFN₂O₃S
• Synonyms: C₂₁H₁₆BrFN₂O₃S
• CAS NO: 1613712-46-1
• Molecular Weight: 475.338
• Mol File: 1613712-46-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₂₁H₁₆BrFN₂O₃S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₁H₁₆BrFN₂O₃S(1613712-46-1)
• EPA Substance Registry System: C₂₁H₁₆BrFN₂O₃S(1613712-46-1)

Safety Data

• Hazardous Substances Data: 1613712-46-1(Hazardous Substances Data)

Upstream product

• 875639-15-9 5-bromo-3-iodo-1-(4-methylbenzene-1-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 762287-59-2 (3-fluoro-2-methoxyphenyl)boronic acid 

Downstream Products

• 1613712-47-2 C₂₅H₁₉FN₂O₃S₂ 
• 1613712-77-8 C₂₉H₂₆FN₃O₅S₂ 
• 1613712-73-4 C₃₂H₃₂FN₃O₅S₂ 
• 1613712-75-6 C₃₁H₂₈FN₃O₅S₂ 
• 1613712-65-4 C₂₆H₂₁FN₂O₄S 
• 1613710-39-6 3-(3-fluoro-2-methoxyphenyl)-5-(thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1613710-56-7 4-((5-(3-(3-fluoro-2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiophen-2-yl)methyl)morpholine 
• 1613710-62-5 5-(5-chlorothiophen-2-yl)-3-(3-fluoro-2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine 
• 1613710-82-9 3-(3-fluoro-2-methoxyphenyl)-5-(5-methylfuran-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1613710-88-5 3-(3-fluoro-2-methoxyphenyl)-5-(5-(pyrrolidin-1-ylmethyl)thiophen-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1613710-89-6 3-(3-fluoro-2-methoxyphenyl)-5-(5-(piperidin-1-ylmethyl)thiophen-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1613710-90-9 4-(5-(3-(3-fluoro-2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazol-2-yl)morpholine 
• 1613710-94-3 N-(tert-butyl)-3-(3-(3-fluoro-2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylbenzenesulfonamide 
• 1613710-96-5 3-(3-fluoro-2-methoxyphenyl)-5-(3-(pyrrolidin-1-ylsulfonyl)phenyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors

The present invention relates to compounds described by Formula I: salts thereof, their synthesis, and their use as ITK and JAK3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, Crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention.